These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24398459)

  • 1. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
    Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the cassette-dosing approach to assess brain penetration in drug discovery.
    Liu X; Ding X; Deshmukh G; Liederer BM; Hop CE
    Drug Metab Dispos; 2012 May; 40(5):963-9. PubMed ID: 22328585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
    Fujii S; Setoguchi C; Kawazu K; Hosoya K
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
    Doran AC; Osgood SM; Mancuso JY; Shaffer CL
    Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
    Bundgaard C; Jensen CJ; Garmer M
    Drug Metab Dispos; 2012 Mar; 40(3):461-6. PubMed ID: 22112383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
    Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
    Sun A; Wang J
    Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.